Search results
FDA investigating cancer risk linked to CAR-T cell therapy
BioPharma Dive via Yahoo Finance· 6 months agoThe Food and Drug Adminsitration is investigating whether CAR-T cell therapies like Novartis’...
FDA approves CAR-T therapies from J&J, Bristol Myers for earlier myeloma use
BioPharma Dive via Yahoo Finance· 1 month agoThe FDA quickly followed last week’s clearance of Bristol Myers’ Abecma with an OK for J&J’s...
Donor CAR T Cells Show Promise as Cancer Treatment in Early Human Trial
Gizmodo via Yahoo News· 1 year agoAn experimental treatment that uses donor white blood cells to fend off cancer continues to show...
CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies
Zacks via Yahoo Finance· 6 months agoThe FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell...
EMA recommends earlier use of Bristol Myers cell therapy for multiple myeloma
BioPharma Dive via Yahoo Finance· 4 months agoThe opinion would allow Abecma to be prescribed after two standard therapies and is the latest sign...
Multiple Myeloma vs. Leukemia: What Are the Differences?
Verywell Health via Yahoo News· 2 years agoMultiple myeloma and leukemia are cancers that both start in blood cells, but they are two very...
FDA warns of secondary cancer risk tied to CAR-T therapies that treat cancer
CNN via Yahoo News· 4 months agoThe US Food and Drug Administration has issued a new warning about the possible risk of secondary...
Blood cancer multiple myeloma, once a death sentence, is now highly treatable. Here's why
USA TODAY via Yahoo News· 9 months agoAfter Judith Harding was diagnosed with multiple myeloma in 2009, she decided to retire, sold her...
J&J secures EMA backing for earlier CAR-T use in multiple myeloma
BioPharma Dive via Yahoo Finance· 3 months agoEuropean drug regulators recommended clearing J&J and Legend Biotech's Carvykti for use as early as...
CAR-T for lupus: the ‘tip of the iceberg’ for cell therapy in autoimmune disease
BioPharma Dive via Yahoo Finance· 4 months agoSince a landmark paper in 2022, drugmakers have begun nearly a dozen trials of cell therapies for...